RPT-Cubist sales force seen as potential boon for Merck intestinal drug
December 10, 2014 at 08:50 AM EST
Dec 9 (Reuters) - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.